HDAC9 and cancer: Previous published data with belinostat in vitro cancer models have demonstrated a potent antiproliferative and HDAC inhibitory activity and inhibition proliferation of a large variety of human cancer cell lines. In vivo, belinostat inhibits growth in human tumour xenografts without apparent toxicity to the host mice [9].